MDX 2001
Alternative Names: MDX-2001Latest Information Update: 28 Jun 2024
Price :
$50 *
At a glance
- Originator ModeX Therapeutics Inc
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 12 Jun 2024 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Monotherapy, Metastatic disease) in USA (IV) (NCT06239194)
- 08 May 2024 US FDA approves IND application for MDX 2001 in Solid tumour
- 07 May 2024 ModeX Therapeutics plans a phase I/IIa trial for Solid tumours (Monotherapy, Late-stage disease, Metastatic disease) (IV, Infusion) in second quarter of 2024 (NCT06239194)